FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891551472> ?p ?o ?g. }

• W2891551472 endingPage "TPS11081" @default.
• W2891551472 startingPage "TPS11081" @default.
• W2891551472 abstract "TPS11081 Background: AAS is an aggressive soft tissue sarcoma (STS) of endothelial cell origin with an expected median overall survival of 8-12 months. Pazopanib (P) is approved for treatment of advanced STS following progression on chemotherapy. In a retrospective study of 40 AAS patients treated with single agent P the median PFS was 3.1 months and median OS 9.9 months with no complete responses. Endoglin is an essential angiogenic receptor expressed on AAS that is upregulated following VEGF inhibition, and TRC105, an endoglin antibody, given with P produced durable complete responses in AAS patients with median PFS of 5.6 months in refractory patients including those receiving prior P. The TAPPAS trial is the first randomized Phase 3 trial performed in AAS, and was initiated following protocol assistance from the EMA and Special Protocol Assessment from the FDA. Methods: TAPPAS is a randomized multicenter study of TRC105/P vs P alone in the United States and Europe that is actively enrolling cutaneous and non-cutaneous AAS patients and incorporates an adaptive enrichment design. Key inclusion criteria: 0, 1 or 2 prior lines of therapy, ECOG ≤ 1. Primary endpoint is PFS and secondary endpoints include ORR and OS. The initial sample size of 124 patients, followed until 95 PFS events, provides more than 80% power to detect a hazard ratio of 0.55. At the time of interim analysis, projected to occur upon the occurrence of 40 events in approximately 70 patients, the result will be classified as belonging to either the favorable, promising, enrichment or unfavorable zones, based on conditional power. The sample size and PFS events will be unchanged in the favorable and unfavorable zones, and will be increased to a total of 200 patients followed for 170 PFS events in the promising zone. The trial will enroll 100 additional patients, with cutaneous disease only, in the enrichment zone and will follow them until 110 events are observed in the total cutaneous population. An independent DMC will follow the trial for safety and futility. The adaptive design requires the enrollment of fewer patients, preserves type-1 error, and protects power to detect a clinically meaningful survival benefit. (NCT 02979899). Clinical trial information: NCT02979899." @default.
• W2891551472 created "2018-09-27" @default.
• W2891551472 creator A5000700279 @default.
• W2891551472 creator A5005702417 @default.
• W2891551472 creator A5020672869 @default.
• W2891551472 creator A5028145932 @default.
• W2891551472 creator A5031037291 @default.
• W2891551472 creator A5031649042 @default.
• W2891551472 creator A5034066580 @default.
• W2891551472 creator A5040082039 @default.
• W2891551472 creator A5048969933 @default.
• W2891551472 creator A5054595254 @default.
• W2891551472 creator A5056823515 @default.
• W2891551472 creator A5061366384 @default.
• W2891551472 creator A5062273071 @default.
• W2891551472 creator A5067779080 @default.
• W2891551472 creator A5068677359 @default.
• W2891551472 creator A5069135591 @default.
• W2891551472 creator A5073906112 @default.
• W2891551472 creator A5077414729 @default.
• W2891551472 date "2017-05-20" @default.
• W2891551472 modified "2023-09-30" @default.
• W2891551472 title "Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS)." @default.
• W2891551472 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps11081" @default.
• W2891551472 hasPublicationYear "2017" @default.
• W2891551472 type Work @default.
• W2891551472 sameAs 2891551472 @default.
• W2891551472 citedByCount "6" @default.
• W2891551472 countsByYear W28915514722018 @default.
• W2891551472 countsByYear W28915514722019 @default.
• W2891551472 countsByYear W28915514722020 @default.
• W2891551472 countsByYear W28915514722023 @default.
• W2891551472 crossrefType "journal-article" @default.
• W2891551472 hasAuthorship W2891551472A5000700279 @default.
• W2891551472 hasAuthorship W2891551472A5005702417 @default.
• W2891551472 hasAuthorship W2891551472A5020672869 @default.
• W2891551472 hasAuthorship W2891551472A5028145932 @default.
• W2891551472 hasAuthorship W2891551472A5031037291 @default.
• W2891551472 hasAuthorship W2891551472A5031649042 @default.
• W2891551472 hasAuthorship W2891551472A5034066580 @default.
• W2891551472 hasAuthorship W2891551472A5040082039 @default.
• W2891551472 hasAuthorship W2891551472A5048969933 @default.
• W2891551472 hasAuthorship W2891551472A5054595254 @default.
• W2891551472 hasAuthorship W2891551472A5056823515 @default.
• W2891551472 hasAuthorship W2891551472A5061366384 @default.
• W2891551472 hasAuthorship W2891551472A5062273071 @default.
• W2891551472 hasAuthorship W2891551472A5067779080 @default.
• W2891551472 hasAuthorship W2891551472A5068677359 @default.
• W2891551472 hasAuthorship W2891551472A5069135591 @default.
• W2891551472 hasAuthorship W2891551472A5073906112 @default.
• W2891551472 hasAuthorship W2891551472A5077414729 @default.
• W2891551472 hasConcept C121332964 @default.
• W2891551472 hasConcept C121608353 @default.
• W2891551472 hasConcept C126322002 @default.
• W2891551472 hasConcept C141071460 @default.
• W2891551472 hasConcept C142424586 @default.
• W2891551472 hasConcept C142724271 @default.
• W2891551472 hasConcept C143998085 @default.
• W2891551472 hasConcept C168563851 @default.
• W2891551472 hasConcept C203092338 @default.
• W2891551472 hasConcept C207103383 @default.
• W2891551472 hasConcept C2778019345 @default.
• W2891551472 hasConcept C2778256501 @default.
• W2891551472 hasConcept C2778439243 @default.
• W2891551472 hasConcept C2778629024 @default.
• W2891551472 hasConcept C2778695046 @default.
• W2891551472 hasConcept C2779490328 @default.
• W2891551472 hasConcept C44249647 @default.
• W2891551472 hasConcept C61943457 @default.
• W2891551472 hasConcept C71924100 @default.
• W2891551472 hasConcept C87355193 @default.
• W2891551472 hasConceptScore W2891551472C121332964 @default.
• W2891551472 hasConceptScore W2891551472C121608353 @default.
• W2891551472 hasConceptScore W2891551472C126322002 @default.
• W2891551472 hasConceptScore W2891551472C141071460 @default.
• W2891551472 hasConceptScore W2891551472C142424586 @default.
• W2891551472 hasConceptScore W2891551472C142724271 @default.
• W2891551472 hasConceptScore W2891551472C143998085 @default.
• W2891551472 hasConceptScore W2891551472C168563851 @default.
• W2891551472 hasConceptScore W2891551472C203092338 @default.
• W2891551472 hasConceptScore W2891551472C207103383 @default.
• W2891551472 hasConceptScore W2891551472C2778019345 @default.
• W2891551472 hasConceptScore W2891551472C2778256501 @default.
• W2891551472 hasConceptScore W2891551472C2778439243 @default.
• W2891551472 hasConceptScore W2891551472C2778629024 @default.
• W2891551472 hasConceptScore W2891551472C2778695046 @default.
• W2891551472 hasConceptScore W2891551472C2779490328 @default.
• W2891551472 hasConceptScore W2891551472C44249647 @default.
• W2891551472 hasConceptScore W2891551472C61943457 @default.
• W2891551472 hasConceptScore W2891551472C71924100 @default.
• W2891551472 hasConceptScore W2891551472C87355193 @default.
• W2891551472 hasIssue "15_suppl" @default.
• W2891551472 hasLocation W28915514721 @default.
• W2891551472 hasOpenAccess W2891551472 @default.
• W2891551472 hasPrimaryLocation W28915514721 @default.
• W2891551472 hasRelatedWork W1593659046 @default.
• W2891551472 hasRelatedWork W1805852575 @default.
• W2891551472 hasRelatedWork W2154171266 @default.

• next